Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) is expected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect Black Diamond Therapeutics to post earnings of ($0.31) per share for the quarter.
Black Diamond Therapeutics Trading Down 5.0 %
NASDAQ BDTX opened at $1.91 on Tuesday. The firm has a market cap of $108.08 million, a price-to-earnings ratio of -1.44 and a beta of 2.51. The company has a 50 day moving average of $2.27 and a 200-day moving average of $3.29. Black Diamond Therapeutics has a 1-year low of $1.88 and a 1-year high of $7.66.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a report on Wednesday, November 6th.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
Read More
- Five stocks we like better than Black Diamond Therapeutics
- Energy and Oil Stocks Explained
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- How to Invest in the FAANG Stocks
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
